|
Market Closed -
Nasdaq
16:00:00 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 0.9812 USD | -1.41% |
|
-8.30% | -83.97% |
Projected Income Statement: Actuate Therapeutics, Inc.
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| EBIT 1 | - | -25.16 | -22.5 | -21.82 | -26.61 | -31.56 |
| Change | - | - | 10.59% | 3.01% | -21.97% | -18.59% |
| Interest Paid | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| Net income | -24.74 | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| Announcement Date | 4/9/24 | 3/13/25 | 3/26/26 | - | - | - |
1USD in Million
Estimates
Forecast Balance Sheet: Actuate Therapeutics, Inc.
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| Announcement Date | 4/9/24 | 3/13/25 | 3/26/26 | - | - | - |
Estimates
Cash Flow Forecast: Actuate Therapeutics, Inc.
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| CAPEX 1 | - | 0.054 | 0.058 | 0.058 |
| Change | - | - | 7.41% | 0% |
| Free Cash Flow (FCF) 1 | -22.23 | -21.24 | -26.68 | -31.12 |
| Change | - | 4.46% | -25.65% | -16.63% |
| Announcement Date | 3/26/26 | - | - | - |
1USD in Million
Estimates
Forecast Financial Ratios: Actuate Therapeutics, Inc.
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
Profitability | |||||||
| EBITDA Margin (%) | - | - | - | - | - | - | - |
| EBIT Margin (%) | - | - | - | - | - | - | - |
| EBT Margin (%) | - | - | - | - | - | - | - |
| Net margin (%) | - | - | - | - | - | - | - |
| FCF margin (%) | - | - | - | - | - | - | - |
| FCF / Net Income (%) | - | - | - | - | - | - | - |
Profitability | |||||||
| ROA | - | -132.96% | -255.41% | -120.4% | - | - | - |
| ROE | - | -442.4% | 1,252.81% | -553.75% | - | - | - |
Financial Health | |||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - | - |
Capital Intensity | |||||||
| CAPEX / Current Assets (%) | - | - | - | - | - | - | - |
| CAPEX / EBITDA (%) | - | - | - | - | - | - | - |
| CAPEX / FCF (%) | - | - | - | - | -0.25% | -0.22% | -0.19% |
Items per share | |||||||
| Cash flow per share 1 | 16.89 | 1.75 | 0.4424 | 0.5661 | - | - | - |
| Change | - | -89.64% | -74.72% | 27.95% | - | - | - |
| Dividend per Share 1 | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - |
| Book Value Per Share 1 | -62.21 | -58.93 | 0.005334 | 0.3409 | - | - | - |
| Change | - | 5.27% | 100.01% | 6,290.83% | - | - | - |
| EPS 1 | -16.65 | -17.24 | -3.259 | -1.057 | - | - | - |
| Change | - | -3.55% | 81.1% | 67.55% | - | - | - |
| Nbr of stocks (in thousands) | - | - | 19,532 | 23,243 | - | - | - |
| Announcement Date | 4/9/24 | 4/9/24 | 3/13/25 | 3/26/26 | - | - | - |
1USD
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | - | - |
| PBR | - | - |
| EV / Sales | - | - |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.9812USD
Average target price
11.68USD
Spread / Average Target
+1,090.72%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ACTU Stock
- Financials Actuate Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
